US2013123200A1PendingUtilityA1

Mammalian cell surface antigens; related reagents

Assignee: MERCK SHARP & DOHMEPriority: Aug 16, 1996Filed: Jan 15, 2013Published: May 16, 2013
Est. expiryAug 16, 2016(expired)· nominal 20-yr term from priority
C07K 14/47A61K 38/00C07K 16/28C07K 14/705A61K 2039/55516A61P 37/02Y10S435/81A61P 37/04C07K 2317/70A61K 39/39Y10S435/975C07K 2319/00C07K 16/2878C07K 14/70578
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.

Claims

exact text as granted — not AI-modified
1 - 22 . (canceled) 
     
     
         23 . A substantially pure polypeptide comprising an extracellular domain of SEQ ID NO:4. 
     
     
         24 . The polypeptide of  claim 23 , wherein the polypeptide is conjugated to a chemical moiety. 
     
     
         25 . The polypeptide of  claim 23 , wherein the polypeptide is fused to a heterologous protein. 
     
     
         26 . The polypeptide of  claim 25 , wherein the heterologous protein is selected from the group consisting of luciferase, bacterial β-galactosidase, trpE, Protein A, β-lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and His 6 (SEQ ID NO:8). 
     
     
         27 . A pharmaceutical formulation comprising the polypeptide of  claim 23  and a pharmaceutically and physiologically acceptable carrier. 
     
     
         28 . A substantially pure polypeptide comprising the amino acid sequence of SEQ ID NO:4. 
     
     
         29 . A pharmaceutical formulation comprising the polypeptide of  claim 28  and a pharmaceutically and physiologically acceptable carrier.

Join the waitlist — get patent alerts

Track US2013123200A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.